| Autor: |
Shah, Pratish H., McGarry, Ronald C. |
| Předmět: |
|
| Zdroj: |
American Journal of Hematology/Oncology; Oct2009, Vol. 8 Issue 10, p497-499, 3p |
| Abstrakt: |
The article discusses several studies conducted by different groups regarding the use of adjuvant chemotherapy for survival benefit to patients with stage IB non-small cell lung cancer (NSCLC). The meta-analysis of Great Britain's Medical Research Council published in 1995 was the first one to suggest the benefit of chemotherapy in NSCLC after reviewing 52 trials on 10,000 patients. Studies that shows significant improvement of overall survival (OS) rates of cancer patients through adjuvant chemotherapy include the International Lung Adjuvant Trial (IALT) study, National Cancer Institute of Canada (NCI-C) study, and the Cancer and Leukemia Group B (CALGB) 9633 trial. The CALGB study recommends to consider adjuvant therapy to patients with tumor size of 4 centimeters or larger. |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
